目的 探讨局限性肺切除术前应用吉非替尼辅助治疗老年非小细胞肺癌(NSCLC)的有效性和安全性.方法 将92例行局限性肺切除术的老年非小细胞肺癌患者分为化疗组(术前接受吉非替尼辅助化疗,n=52)和对照组(仅接受局限性肺切除术,n=40),对两组患者的近期疗效、1年期生存率和生活质量进行评估和比较.结果 化疗组的手术切除率为92.3%,术后1年期生存率为78.8%,肿瘤复发和转移率为3.8%;对照组手术切除率为77.5%,术后1年期生存率为70.0%,肿瘤复发和转移率为17.5%.化疗组患者的手术切除率高于对照组,肿瘤复发转移率低于对照组,差异均有统计学意义(P＜0.05);化疗组1年期生存率高于对照组,但两组比较差异无统计学意义(P＞0.05).化疗组主要术后并发症发生率为15.4%,对照组为15.0%,两组比较差异无统计学意义(P＞0.05).术后1年,化疗组生存质量评分为(35.48±14.52)分,低于对照组的(42.35±15.67)分,差异有统计学意义(P＜0.05).结论 吉非替尼术前辅助化疗可以提高老年非小细胞肺癌患者的近期疗效和生活质量,降低1年复发转移率.%To investigate the efficacy and safety of Gefitinib adjuvant - chemotherapy applied before localized pneumononectomy in elderly patients with non - small cell lung cancer ( NSCLC ) . Methods Totally 92 NSCLC patients were divided into 2 groups: 52 patients in chemotherapy group were given 250 mg/day for 28 days before localized pneumonecto-my and 40 patients in control group just received the pnumononectomy. The outcomes of short - term effect, one - year survival ratio, and one -year life quality were evaluated. Results The ablation ratio of lung cancer, one - year- survival ratio, one -year recurrence and metastasis ratio were respectively 92. 3% , 78. 8% and 3. 8% in the chemotherapy group; as compared with 77. 5% , 70. 0% and 17. 5% in the control group, the differences of ablation ratio and recurrence ratio were statistically significant ( P < 0. 05 ). The one - year survival ratio in the chemotherapy group was higher in the chemotherapy group than in the control group, but with no significant difference ( P > 0. 05 ). The prevalence of major postsurgical complication was 15.4% in the chemotherapy group, and 15.0% in the control group ( P >0. 05 ). The one - year life quality post - surgically was ( 35. 48 ± 14. 52) in the chemotherapy, being significantly lower than ( 42. 35 ±15. 67 ) in the control group ( P < 0. 05 ). Conclusion (iefitinib adjuvant - chemotherapy pre - surgically can raise the short - term efficacy and life quality and reduce one - year recurrence and metastasis ratio in elderly patients with NSCLC.
展开▼
